Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors
- PMID: 37442801
- PMCID: PMC10447168
- DOI: 10.1111/1759-7714.15032
Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors
Abstract
Background: Inflammation in non-small cell lung cancer (NSCLC) may impair the response to immune checkpoint inhibitors (ICIs) and can be indicated by peripheral blood inflammatory indexes. 2-deoxy-2-[18 F]fluoro-D-glucose positron emission tomography/computed tomography ([18 F] FDG-PET/CT) may be used as a marker of inflammation by measuring glucose metabolism in different colonic sites.
Methods: This retrospective analysis aimed to investigate the correlation between [18 F] FDGPET/CT SUVratio in six gastrointestinal districts, the spleen, the pharynx and the larynx alongside the most avid tumor lesion with peripheral blood inflammatory indexes, including the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammatory index (SII, i.e., NLR times platelets) and lactate dehydrogenase (LDH), in patients with [18 F] FDG-PET/CT staged IV NSCLC who received first-line immune checkpoint inhibitors (ICIs). The role of SUVratios and peripheral blood inflammatory indexes in predicting overall survival (OS) and progression-free survival (PFS) was then explored.
Results: A total of 43 patients were treated with first-line ICI alone (58%) or in combination with chemotherapy (42%). A significant correlation was only found between the rectosigmoid SUVratio and NLR (p = 0.0465). NLR >5.5 and LDH > 333.5 were associated with a worse OS (p = 0.033 and p = 0.009, respectively). The SII was associated with a worse PFS in patients treated with ICI alone (p = 0.033). None of the SUVratios were significantly associated with OS or PFS, although a high left colon SUVratio showed a trend toward a worse PFS.
Conclusion: There was no significant correlation between [18 F]FDG PET/CT uptake in different anatomical sites, and in the tumor, and systemic immune-inflammatory indexes. The prognostic role of high left colon SUVratio deserves further investigation.
Keywords: NLR; gut microbiome; immune checkpoint inhibitor; immunotherapy; lung cancer.
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
Giuseppe Luigi Banna reports personal fees from AstraZeneca, Astellas, travel and conference expenses from Janssen, outside the submitted work. Vanesa Gregorc declared consultant/advisor's fees from Boehringer Ingelheim, Bistol Myear Squibb, and Janssen outside the submitted work. Silvia Novello declared speaker bureau/advisor's fee from Eli Lilly, MSD, Roche, Bristol Myer Squibb, Amgen, Takeda, Pfizer, Thermo Fisher Scientific, Astra Zeneca and Boehringer Ingelheim outside the submitted work. The other authors have nothing to declare.
Figures


Similar articles
-
Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.Eur J Nucl Med Mol Imaging. 2021 May;48(5):1550-1559. doi: 10.1007/s00259-020-05081-6. Epub 2020 Oct 31. Eur J Nucl Med Mol Imaging. 2021. PMID: 33128571
-
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.Eur J Cancer. 2021 Jun;150:99-107. doi: 10.1016/j.ejca.2021.03.020. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892411
-
Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.Front Immunol. 2022 Nov 17;13:1014063. doi: 10.3389/fimmu.2022.1014063. eCollection 2022. Front Immunol. 2022. PMID: 36466905 Free PMC article.
-
The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.Hell J Nucl Med. 2021 Sep-Dec;24(3):186-198. doi: 10.1967/s002449912402. Epub 2021 Dec 17. Hell J Nucl Med. 2021. PMID: 34901959
-
The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4661-4676. doi: 10.1007/s00259-022-05918-2. Epub 2022 Aug 6. Eur J Nucl Med Mol Imaging. 2022. PMID: 35932329 Free PMC article.
Cited by
-
Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer.Lung. 2023 Dec;201(6):603-610. doi: 10.1007/s00408-023-00649-z. Epub 2023 Oct 31. Lung. 2023. PMID: 37906295
-
The role of baseline 18F-FDG PET/CT for survival prognosis in NSCLC patients undergoing immunotherapy: a systematic review and meta-analysis.Ther Adv Med Oncol. 2024 Nov 4;16:17588359241293364. doi: 10.1177/17588359241293364. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39502406 Free PMC article. Review.
-
The association of immune-inflammation indices at multiple time points with treatment response and survival in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.World J Surg Oncol. 2025 May 16;23(1):195. doi: 10.1186/s12957-025-03833-y. World J Surg Oncol. 2025. PMID: 40380206 Free PMC article.
-
Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.PLoS One. 2024 Nov 1;19(11):e0312605. doi: 10.1371/journal.pone.0312605. eCollection 2024. PLoS One. 2024. PMID: 39485761 Free PMC article.
-
Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Front Oncol. 2025 May 16;15:1532343. doi: 10.3389/fonc.2025.1532343. eCollection 2025. Front Oncol. 2025. PMID: 40452837 Free PMC article.
References
-
- Cvetkovic L, Régis C, Richard C, Derosa L, Leblond A, Malo J, et al. Physiologic colonic uptake of 18F‐FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2021;48(5):1550–1559. 10.1007/s00259-020-05081-6 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical